Coya Historical Balance Sheet
| COYA Stock | 6.09 0.05 0.83% |
Trend analysis of Coya Therapeutics, Common balance sheet accounts such as Other Current Liab of 1.1 M, Total Current Liabilities of 2.9 M or Total Stockholder Equity of 37.4 M provides information on Coya Therapeutics,'s total assets, liabilities, and equity, which is the actual value of Coya Therapeutics, Common to its prevalent stockholders. By breaking down trends over time using Coya Therapeutics, balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Coya Therapeutics, Common latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Coya Therapeutics, Common is a good buy for the upcoming year.
Coya |
About Coya Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Coya Therapeutics, Common at a specified time, usually calculated after every quarter, six months, or one year. Coya Therapeutics, Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Coya Therapeutics, and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Coya currently owns. An asset can also be divided into two categories, current and non-current.
Coya Therapeutics, Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Coya Therapeutics, assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Coya Therapeutics, Common books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Property Plant And Equipment Net
The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.Cash And Short Term Investments
Short Term Investments is an account in the current assets section of Coya Therapeutics, Common balance sheet. This account contains Coya Therapeutics, investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Coya Therapeutics, Common fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Most accounts from Coya Therapeutics,'s balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Coya Therapeutics, Common current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Coya Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. At present, Coya Therapeutics,'s Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 37.4 M, whereas Other Current Liabilities is forecasted to decline to about 1.1 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Cash | 4.3M | 5.9M | 32.6M | 34.3M | Accounts Payable | 857.6K | 1.8M | 1.2M | 1.2M |
Coya Therapeutics, balance sheet Correlations
Click cells to compare fundamentals
Coya Therapeutics, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Coya Therapeutics, Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Coya Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Coya Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Coya Therapeutics, Common Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Coya Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Coya Therapeutics,. If investors know Coya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Coya Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Revenue Per Share 0.687 | Return On Assets (0.29) | Return On Equity (0.51) |
The market value of Coya Therapeutics, Common is measured differently than its book value, which is the value of Coya that is recorded on the company's balance sheet. Investors also form their own opinion of Coya Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Coya Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Coya Therapeutics,'s market value can be influenced by many factors that don't directly affect Coya Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Coya Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Coya Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Coya Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.